Candel Therapeutics, Inc.CADLEarnings & Financial Report
Candel Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing oncolytic immunotherapies for cancer treatment. Its product pipeline covers solid tumors and hematological malignancies, serving global oncology markets and addressing unmet medical needs for patients with limited treatment options.
Revenue
$31.0K
Gross Profit
N/A
Operating Profit
$-8.9M
Net Profit
$-8.7M
Gross Margin
N/A
Operating Margin
-28648.4%
Net Margin
-28025.8%
YoY Growth
0.0%
EPS
$-0.30
Candel Therapeutics, Inc. Q3 FY2022 Financial Summary
Candel Therapeutics, Inc. reported revenue of $31.0K (up 0.0% YoY) for Q3 FY2022, with a net profit of $-8.7M (up 46.2% YoY) (-28025.8% margin).
Key Financial Metrics
| Total Revenue | $31.0K |
|---|---|
| Net Profit | $-8.7M |
| Gross Margin | N/A |
| Operating Margin | -28648.4% |
| Report Period | Q3 FY2022 |
Candel Therapeutics, Inc. Annual Revenue by Year
Candel Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $125.0K).
| Year | Annual Revenue |
|---|---|
| 2022 | $125.0K |
Candel Therapeutics, Inc. Quarterly Revenue & Net Profit History
Candel Therapeutics, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2023 | $102.0K | +229.0% | $-8.8M | -8622.5% |
| Q4 FY2022 | $32.0K | — | $-5.1M | -15884.4% |
| Q3 FY2022 | $31.0K | +0.0% | $-8.7M | -28025.8% |
| Q2 FY2022 | $31.0K | +0.0% | $-4.1M | -13383.9% |
| Q1 FY2022 | $31.0K | — | $-874.0K | -2819.4% |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | |
|---|---|---|---|---|---|
| Revenue | $31000 | $31000 | $31000 | $32000 | $102000 |
| YoY Growth | N/A | 0.0% | 0.0% | N/A | 229.0% |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | |
|---|---|---|---|---|---|
| Assets | $101.6M | $93.3M | $85.0M | $77.7M | $67.2M |
| Liabilities | $37.8M | $33.2M | $32.9M | $30.0M | $27.6M |
| Equity | $63.8M | $60.1M | $52.1M | $47.7M | $39.7M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | |
|---|---|---|---|---|---|
| Operating CF | $-8.1M | $-7.1M | $-9.4M | $-6.9M | $-10.8M |